Skip to main content

AT1026: Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

PACTG1026S-Pharmacokinetic Properties of Antiretroviral Drugs During Pregnancy


Supportive Infectious Diseases Studies

Diseases Treated:

HIV Infection

Eligibility Overview:

This is a non-therapeutic clinical trial that is only open to St. Jude patients.

  • The subject has been enrolled on IMPAACT P1025.


Studies have shown that women and men differ in how their bodies metabolize certain drugs. Pregnancy may have an additional effect on drug metabolism for women. Pregnant women experience unique physiological changes that may result in clinically significant changes in drug pharmacokinetics (the way the body uses the drug) and pharmacodynamics (how the drug acts on the body).

This study will evaluate the pharmacokinetics and pharmacodynamics of currently prescribed antiretroviral drugs and interacting combinations of these drugs in pregnant HIV-infected women.


  • Evaluate the pharmacokinetics and pharmacodynamics of selected antiretroviral drugs currently used in therapy of pregnant HIV-infected women
  • Compare antiretroviral drug levels in blood from the mother and her baby at time of birth


  • The subject has been enrolled on IMPAACT P1025.

Principal Investigator

Katherine Knapp, MD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105  USA
Voice: 1-888-226-4343 or 901-595-4055
24-Hour Emergency Access Pager: 1-800-349-4334

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.